Travere Therapeutics, Inc. (NASDAQ:TVTX) Q1 2026 Earnings Call Transcript
Operator: Hello, and welcome to Travere Therapeutics, Inc.’s first quarter 2026 financial results conference call. Today’s call is being recorded.
Travere Therapeutics Inc. (TVTX)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | 50,000 | $1,485,500 | +164% | 0.01% | |
| 2. | Fisher Asset Management Ken Fisher | 33,996 | $1,010,023 | 0% | |
| 3. | Leucadia National Ian Cumming And Joseph Steinberg | 4,837 | $143,707 | +62% | 0% |
| 4. | Bayforest Capital Theodoros Tsagaris | 3,512 | $104,342 | 0.12% | |
| 5. | 45,000 | $57,036 | +310% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $17.85 | 5,000 | $89,250.00 | 245,556 | 2017-06-14 | Filing | |
| $15.31 | 5,000 | $76,564.50 | 52,000 | 2016-03-04 | Filing | |
| $8.60 | 15,000 | $129,049.50 | 35,000 | 2014-11-25 | Filing | |
| $8.38 | 6,100 | $51,118.00 | 129,165 | 2014-11-21 | Filing | |
| $8.50 | 8,700 | $73,950.00 | 371,756 | 2014-11-21 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $46.65 | 4,500 | $209,925.00 | 37,500 | 2026-05-05 | Filing | |
| $45.00 | 8,000 | $360,000.00 | 87,500 | 2026-05-04 | Filing | |
| $43.95 | 2,763 | $121,433.85 | 115,474 | 2026-05-06 | Filing | |
| $43.95 | 2,076 | $91,240.20 | 105,211 | 2026-05-06 | Filing | |
| $46.65 | 2,174 | $101,417.10 | 107,287 | 2026-05-05 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 4,045,812 | $120,201,075 | 0% | |
| 2. | 52,933,000 | $66,936,425 | 1.55% | |
| 3. | 1,798,466 | $53,432,425 | 0.73% | |
| 4. | 1,709,139 | $50,778,520 | 0% | |
| 5. | 1,557,196 | $46,264,293 | 1.46% |
News See All
Billionaire Joe Edelman's 10 Stock Picks with Huge Upside Potential
Joseph Edelman, the billionaire chief of New York-based Perceptive Advisors, specializes in the biotechnology and life sciences sectors.
Is Travere Therapeutics, Inc. (TVTX) A Good Stock To Buy Now?
Is TVTX a good stock to buy? We came across a bullish thesis on Travere Therapeutics, Inc. on BioEquity Watch’s Substack. In this article, we will summarize the bulls’ thesis on TVTX.
10 Stocks With Monster Returns
Notably, investors poured funds into industries with promising growth prospects, namely semiconductor and quantum computing, while some favored pharmaceutical players thanks to progress on their pipeline...
10 Overlooked Growth Stocks to Buy Now
On April 14, Tom Lee, Fundstrat's Head of Research, joined CNBC's 'Power Lunch' to discuss his outlook on equities.
Piper Sandler Increases Target Price for Travere Therapeutics (TVTX)
On February 19, Travere Therapeutics Inc. (NASDAQ:TVTX) released the fourth quarter earnings report. The company registered U.S.
10 Most Shorted Biotech Stocks to Buy According to Hedge Funds
On February 5, J.P. Morgan shared its views on trends that are expected to define healthcare in 2026.
Travere Therapeutics, Inc. (TVTX): A Bull Case Theory
We came across a bullish thesis on Travere Therapeutics, Inc. on HalfBakedInnovations’s Substack by Biotech Distilled.
Travere Therapeutics (TVTX) Reports 144% Annual Growth in Filspari Sales for 2025
Travere Therapeutics Inc. (NASDAQ:TVTX) is one of the best stocks for beginners with little money in 2026.
10 Best Stocks for Beginners with Little Money in 2026
On February 19, Joseph Stiglitz, the Nobel Prize-winning economist and ‘The Road to Freedom’ author, joined CNBC's 'Squawk Box' to discuss the state of the economy and argued that conditions are poor...
Hedge Fund Resource Center